EuroBiotech: More Articles of Note

newspapers
(Pixabay)

> SurgiMab moved SGM-101 into phase 3 studies. SGM-101 is a tumor-specific antibody designed for use in colorectal cancer surgery. Release 

> Oryzon published data from a phase 2a Alzheimer’s disease clinical trial. The update showed some of the first 33 patients to complete 24 weeks of follow-up had stable or improving disease. Statement 

> Mereo BioPharma detailed plans to win accelerated approval of navicixizumab on the strength of a phase 2 trial. The disclosure follows a meeting between Mereo and the FDA about the ovarian cancer drug. Release 

Submissions Open

Fierce Innovation Awards: Life Sciences Edition 2020

Submit your entry to demonstrate innovative technologies and services that have the potential to make the greatest impact for biotech and pharma companies.

> Motif Bio filed a meeting request and data related to its antibiotic iclaprim with the FDA. The filing follows indications from the FDA that Motif will need to run another trial to win approval. Statement 

> AC Immune moved its Eli Lilly-partnered tau drug into phase 1. The trial will assess the safety and other features of the drug in healthy volunteers. Release 

> NuCana dosed the first patient in a phase 1 trial of its cordycepin-derived drug. The trial will enroll up to 61 solid tumor patients. Statement 

Suggested Articles

Biogen will develop a gene therapy with the goal of preserving and possibly restoring vision in patients with PRPF31-mutated retinitis pigmentosa.

A month after moving its COVID-19 antibody cocktail into human trials, Regeneron is testing the drug's ability to ward off COVID-19 infection.

Short reports are nothing new, but the aggressive “I’m coming after you” PR from Applied Therapeutics certainly is.